Matches in SemOpenAlex for { <https://semopenalex.org/work/W3100603387> ?p ?o ?g. }
- W3100603387 endingPage "401" @default.
- W3100603387 startingPage "394" @default.
- W3100603387 abstract "Abstract Tremendous progress has been made in treating patients with metastatic melanoma over the past decade. In that timeframe, the FDA has approved 12 novel treatments for patients with advanced unresectable melanoma, comprising both kinase-targeted therapies and immune checkpoint inhibitors (ICI), and five treatments for adjuvant (postoperative) use in patients with high-risk resectable stage III melanoma. It is not known whether outcomes can be further improved by administering kinase inhibitors or ICI in the neoadjuvant (presurgical) setting in patients with high-risk resectable melanomas. Noting research community interest in exploring the neoadjuvant approach for treating melanoma and recognizing that early harmonization of methodologies may expedite the development of therapeutics in this space, the FDA and Melanoma Research Alliance convened a public workshop on November 6, 2019, in National Harbor, Maryland, to discuss key issues. The workshop consisted of 23 faculty and included more than 250 live participants. Topics discussed included opportunities for advancing novel endpoints for regulatory purposes as well as translational research, clinical trial design considerations, and strategies for optimizing patient selection while mitigating risk." @default.
- W3100603387 created "2020-11-23" @default.
- W3100603387 creator A5002954478 @default.
- W3100603387 creator A5005537242 @default.
- W3100603387 creator A5012202516 @default.
- W3100603387 creator A5023174631 @default.
- W3100603387 creator A5025643508 @default.
- W3100603387 creator A5034704814 @default.
- W3100603387 creator A5035427219 @default.
- W3100603387 creator A5035471137 @default.
- W3100603387 creator A5037357027 @default.
- W3100603387 creator A5040901194 @default.
- W3100603387 creator A5052526230 @default.
- W3100603387 creator A5052980036 @default.
- W3100603387 creator A5056132643 @default.
- W3100603387 creator A5059543131 @default.
- W3100603387 creator A5059963442 @default.
- W3100603387 creator A5062916090 @default.
- W3100603387 creator A5067831105 @default.
- W3100603387 creator A5069297078 @default.
- W3100603387 creator A5073571977 @default.
- W3100603387 creator A5077268765 @default.
- W3100603387 creator A5078176723 @default.
- W3100603387 creator A5088220792 @default.
- W3100603387 creator A5088390068 @default.
- W3100603387 creator A5091323110 @default.
- W3100603387 date "2021-01-15" @default.
- W3100603387 modified "2023-10-18" @default.
- W3100603387 title "Neoadjuvant Therapy for Melanoma: A U.S. Food and Drug Administration—Melanoma Research Alliance Public Workshop" @default.
- W3100603387 cites W1950829641 @default.
- W3100603387 cites W1994485684 @default.
- W3100603387 cites W2005494948 @default.
- W3100603387 cites W2055901890 @default.
- W3100603387 cites W2075894019 @default.
- W3100603387 cites W2101760255 @default.
- W3100603387 cites W2103675014 @default.
- W3100603387 cites W2104504726 @default.
- W3100603387 cites W2114903025 @default.
- W3100603387 cites W2115961074 @default.
- W3100603387 cites W2118503880 @default.
- W3100603387 cites W2137723371 @default.
- W3100603387 cites W2156167210 @default.
- W3100603387 cites W2182482244 @default.
- W3100603387 cites W2316247073 @default.
- W3100603387 cites W2521503673 @default.
- W3100603387 cites W2585697071 @default.
- W3100603387 cites W2736281414 @default.
- W3100603387 cites W2752210999 @default.
- W3100603387 cites W2752227448 @default.
- W3100603387 cites W2761072514 @default.
- W3100603387 cites W2762347490 @default.
- W3100603387 cites W2783914781 @default.
- W3100603387 cites W2797309423 @default.
- W3100603387 cites W2798160602 @default.
- W3100603387 cites W2810879984 @default.
- W3100603387 cites W2867613812 @default.
- W3100603387 cites W2892483359 @default.
- W3100603387 cites W2894584497 @default.
- W3100603387 cites W2894796660 @default.
- W3100603387 cites W2905289065 @default.
- W3100603387 cites W2912068031 @default.
- W3100603387 cites W2916647762 @default.
- W3100603387 cites W2947338182 @default.
- W3100603387 cites W2947765148 @default.
- W3100603387 cites W2947779096 @default.
- W3100603387 cites W2947828919 @default.
- W3100603387 cites W2948155539 @default.
- W3100603387 cites W2955181150 @default.
- W3100603387 cites W2963476376 @default.
- W3100603387 cites W2982006800 @default.
- W3100603387 cites W2986355235 @default.
- W3100603387 cites W2998795792 @default.
- W3100603387 cites W3043703771 @default.
- W3100603387 cites W3082456432 @default.
- W3100603387 cites W3087401339 @default.
- W3100603387 cites W3087697977 @default.
- W3100603387 doi "https://doi.org/10.1158/1078-0432.ccr-20-3285" @default.
- W3100603387 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33188142" @default.
- W3100603387 hasPublicationYear "2021" @default.
- W3100603387 type Work @default.
- W3100603387 sameAs 3100603387 @default.
- W3100603387 citedByCount "6" @default.
- W3100603387 countsByYear W31006033872021 @default.
- W3100603387 countsByYear W31006033872022 @default.
- W3100603387 countsByYear W31006033872023 @default.
- W3100603387 crossrefType "journal-article" @default.
- W3100603387 hasAuthorship W3100603387A5002954478 @default.
- W3100603387 hasAuthorship W3100603387A5005537242 @default.
- W3100603387 hasAuthorship W3100603387A5012202516 @default.
- W3100603387 hasAuthorship W3100603387A5023174631 @default.
- W3100603387 hasAuthorship W3100603387A5025643508 @default.
- W3100603387 hasAuthorship W3100603387A5034704814 @default.
- W3100603387 hasAuthorship W3100603387A5035427219 @default.
- W3100603387 hasAuthorship W3100603387A5035471137 @default.
- W3100603387 hasAuthorship W3100603387A5037357027 @default.
- W3100603387 hasAuthorship W3100603387A5040901194 @default.
- W3100603387 hasAuthorship W3100603387A5052526230 @default.
- W3100603387 hasAuthorship W3100603387A5052980036 @default.